THALLOUS CHLORIDE Tl 201 1 mCi/mL Injection, Solution, 1 vial — NDC 69945-120-63 (Billing 69945-0120-63)
This is a package of 1 vial of THALLOUS CHLORIDE Tl 201 1 mCi/mL Injection, Solution from Curium US LLC, marketed since Nov 2015 and currently FDA-listed.
NDC database record
One package, one record: these facts belong to NDC 69945-120-63 alone.
- Record
- FDA NDC Directory package listing · Human prescription drug
- Code segments
- 69945 labeler · 120 product · 63 package
- Listing certified through
- Dec 31, 2026
- Barcode (UPC-A, from the NDC)
- 3 6994512063 2
- FDA record last changed
- Jul 24, 2026
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification
- GSN (GCN sequence number): 065407
- GCN: 27359
- HICL (First Databank): 036464
- AHFS class code: 36:18.00.00
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
Clinical
Patient education
Supplement & herbal interactions
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 3, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per mL | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · quarterly | No Part D plan price is available for this NDC in our data. | |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 4, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 69945-0120-28 69945-120-28 Main listing | 1 VIAL in 1 CAN / 2.8 mL in 1 VIAL | 2015-11-04 | — | Active |
| 69945-0120-56 69945-120-56 | 1 VIAL in 1 CAN / 5.6 mL in 1 VIAL | 2015-11-04 | — | Active |
| 69945-0120-63 You're viewing this | 1 VIAL in 1 CAN / 6.3 mL in 1 VIAL | 2015-11-04 | — | Active |
| 69945-0120-99 69945-120-99 | 1 VIAL in 1 CAN / 9.9 mL in 1 VIAL | 2015-11-04 | — | Active |
Pack size FAQ
What quantity is in this package?
How does this package differ from NDC 69945-0120-28?
What NDC number is used to bill for this package of THALLOUS CHLORIDE Tl 201 1 mCi/mL Injection, Solution?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| THALLOUS CHLORIDE Tl 201 1 mCi/mLthis 69945-0120-63 | Curium | 1 vial | — | — | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Oct 3, 2026
- CMS NADAC weekly file
Availability & generic status
The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.
Where does this data come from?
- FDA Orange Book · refreshed Oct 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII LKG8494WBH
Benzyl alcohol is a clear liquid used as a preservative and solvent in medicines. It helps prevent bacterial and fungal growth and dissolves other ingredients to create uniform liquid formulations.
-
UNII QTT17582CB
A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
-
UNII 451W47IQ8X
Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
-
UNII 55X04QC32I
A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
4 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 3, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
More NDCs from Curium US LLC labeler code 69945
- Technetium Tc 99m Sestamibi 1 mg/mL Injection NDC 69945-092-20
- Technescan PYP Technetium Tc 99m Pyrophosphate 11.9 mg/10mL; 3.2 mg/10mL Injection, Powder, Lyophilized, For Solution NDC 69945-094-20
- Technescan MAG3 Technescan Tc 99m Mertiatide 1 mg Injection, Powder, Lyophilized, For Solution NDC 69945-096-20
- Xenon, Xe-133 5 mCi/mL Gas NDC 69945-097-11
- Xenon, Xe-133 10 mCi/mL Gas NDC 69945-098-21
- Ultra-Technekow V4 Technetium Tc-99m 11 Ci Injection, Solution NDC 69945-110-12
- Pulmotech MAA kit for the preparation of technetium Tc 99m albumin aggregated 2 mg/15mL Injection, Powder, Lyophilized, For Suspension NDC 69945-139-20
- Ultra-Technekow V4 Technetium Tc-99m 14 Ci Injection, Solution NDC 69945-140-13
- Ultra-Technekow V4 Technetium Tc-99m 16 Ci Injection, Solution NDC 69945-160-14
- Ioflupane I 123 2 mCi/mL Injection, Solution NDC 69945-166-05
- BEXLUTRY LUTETIUM OXODOTREOTIDE LU-177 10 mCi/mL Injection NDC 69945-177-01
- GALLIUM CITRATE GA-67 2 mCi/mL Injection, Solution NDC 69945-180-06
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
1 INDICATIONS AND USAGE Thallous Chloride Tl 201 Injection is indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for the following applications: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress Localization of sites of parathyroid hyperactivity pre- and post-operatively in adults with elevated serum calcium and parathyroid hormone levels Thallous Chloride Tl 201 Injection is a radioactive diagnostic drug indicated for use with planar scintigraphy or single-photon emission computed tomography (SPECT) for: Myocardial perfusion imaging in adults for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress Localization of sites of parathyroid hyperactivity pre- and post-operatively in adults with elevated serum calcium and parathyroid hormone levels ( 1 )
⏱️ Dosage and Administration ▾
2 DOSAGE AND ADMINISTRATION • For myocardial perfusion imaging: Planar 37 MBq to 74 MBq (1 mCi to 2 mCi) ( 2.2 ) SPECT 74 MBq to 111 MBq (2 mCi to 3 mCi) ( 2.2 ) For localization of parathyroid hyperactivity, planar or SPECT: 75 MBq to 130 MBq (2 mCi to 3.5 mCi) Administer by intravenous injection. ( 2.2 ) See full prescribing information for administration and imaging instructions and radiation dosimetry information. ( 2.3 , 2.4 )
2.1Radiation Safety – Drug Handling Handle Thallous Chloride Tl 201 Injection with appropriate safety measures to minimize radiation exposure [see Warnings and Precautions ( 5.3 )] . Use waterproof gloves, effective radiation shielding, and other appropriate safety measures when preparing and handling Thallous Chloride Tl 201 Injection. Radiopharmaceuticals should be used by or under the control of healthcare providers who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
2.2Recommended Dose Myocardial Perfusion Imaging in Adults Planar scintigraphy: 37 MBq to 74 MBq (1 mCi to 2 mCi) administered intravenously SPECT: 74 MBq to 111 MBq (2 mCi to 3 mCi) administered intravenously Parathyroid Hyperactivity Localization in Adults Planar or SPECT: 75 MBq to 130 MBq (2 mCi to 3.5 mCi) administered intravenously
2.3Administration and Imaging Instructions Patient Preparation Instruct patients to hydrate before and after Thallous Chloride Tl 201 Injection administration and to void before imaging and frequently thereafter following Thallous Chloride Tl 201 Injection administration [see Warnings and Precautions ( 5.3 )] . Administration Use aseptic technique and radiation shielding when withdrawing and administering Thallous Chloride Tl 201 Injection. Visually inspect the drug for particulate matter and discoloration prior to administration, whenever the solution and container permit.
Do not use if contents are turbid or discolored. Measure the patient dose with a dose calibrator immediately prior to administration. Use within 6 days from the manufacturer’s calibration date or 9 days from the date of manufacture, whichever comes first.
Dispose of unused products in a safe manner in compliance with applicable regulations. Myocardial Perfusion Imaging For resting myocardial studies, begin imaging 10 minutes to 20 minutes after administration of Thallous Chloride Tl 201 Injection. Target-to-background ratios are improved when patients are injected upright and in the fasting state; the upright position reduces the hepatic and gastric thallium-201 concentration.
For exercise stress testing, administer Thallous Chloride Tl 201 Injection at the start of a period of maximum stress, which is sustained for approximately 30 seconds after injection. Begin imaging within 10 minutes after administration to obtain maximum target-to-background ratios. Within 2 hours after the completion of the stress testing, the target-to-background ratios may decrease in lesions that are attributable to transient ischemia.
Parathyroid Hyperactivity Localization For localization of parathyroid hyperactivity, administer Thallous Chloride Tl 201 Injection before, with, or after a minimal dose of a thyroid imaging agent such as sodium pertechnetate Tc 99m injection or sodium iodide I 123 capsules to enable thyroid subtraction imaging.
2.4Radiation Dosimetry Estimated absorbed radiation doses from an intravenous injection of Thallous Chloride Tl 201 Injection are shown in Table 1. Table 1. Estimated Absorbed Radiation Dose per Injected Activity in Organs and Tissues of Adults from Intravenous Administration of Thallous Chloride Tl 201 Injection 1 Organ/ Tissue Absorbed Dose per Unit Activity Administered (mGy/MBq) Adrenals 0.063 Brain 0.057 Breasts 0.034 GB Wall 0.083 GI Tract LLI Wall 0.300 Small Intestine 0.379 Stomach 0.171 ULI Wall 0.297 Heart Wall 0.24… [Excerpted — this section continues on DailyMed.]
💊 Dosage Forms and Strengths ▾
3 DOSAGE FORMS AND STRENGTHS Injection: a clear, colorless solution available in the following strength at calibration time: 207.2 MBq (5.6 mCi) per 5.6 mL (37 MBq (1 mCi) per mL) in a multiple-dose vial Injection: available in the following strength at calibration time in a multiple-dose vial 207.2 MBq (5.6 mCi) per 5.6 mL (37 MBq (1 mCi) per mL) ( 3 )
⛔ Contraindications ▾
4 CONTRAINDICATIONS None. None
⚠️ Warnings and Cautions ▾
5 WARNINGS AND PRECAUTIONS Hypersensitivity Reactions: Anaphylactic reactions characterized by cardiovascular, respiratory, and cutaneous symptoms may occur. Have resuscitation equipment and trained staff readily available. ( 5.1 ) Risk Associated with Stress Testing: Induction of cardiovascular stress may be associated with serious adverse reactions.
Perform stress testing in a setting where cardiac resuscitation equipment and trained staff are readily available. ( 5.2 ) Radiation Risk: Ensure safe handling to minimize radiation exposure to patients and health care providers. ( 2.1 , 5.3 )
5.1Hypersensitivity Reactions Thallous Chloride Tl 201 Injection may cause anaphylactic reactions characterized by cardiovascular, respiratory, and cutaneous symptoms [see Adverse Reactions ( 6 )] . Have resuscitation equipment and trained staff readily available.
5.2Risks Associated with Stress Testing Induction of cardiovascular stress might be associated with serious adverse reactions such as myocardial infarction, arrhythmia, hypotension or hypertension, ECG abnormalities, chest pain, bronchoconstriction, and cerebrovascular events [see Adverse Reactions ( 6 )] . Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. Perform pharmacologic stress in accordance with the pharmacologic stress agent’s prescribing information.
5.3Radiation Risk Thallous Chloride Tl 201 Injection contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void frequently after administration [see Dosage and Administration ( 2.1 , 2.3 )].
5.4Injection Site Reactions and Tissue Damage Injection site reactions and extravasation have been reported after administration of Thallous Chloride Tl 201 Injection [see Adverse Reactions ( 6 )] . Administer Thallous Chloride Tl 201 Injection strictly into the vein to avoid local tissue accumulation and irradiation. Confirm intravenous patency before injection.
🤒 Adverse Reactions ▾
6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions ( 5.1 )] Risk Associated with Stress Testing [see Warnings and Precautions ( 5.2 )] Injection Site Reactions and Tissue Damage [see Warnings and Precautions ( 5.4 )] The following adverse reactions associated with the use of Thallous Chloride Tl 201 Injection were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: Cardiovascular, respiratory, and cerebrovascular disorders: myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events in patients who have undergone stress testing Gastrointestinal disorders: nausea, vomiting, and diarrhea General disorders and administration site conditions: injection site reactions (burning, pain, redness, swelling, warmth, and tissue damage with chronic ulcer formation), chills, fever, and sweating Immune system disorders: hypersensitivity (anaphylaxis, hypotension, shortness of breath, pruritus, flushing, and diffuse rash) The following adverse reactions have been reported.
In patients who have undergone stress testing: myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Adverse reactions in other patients: nausea, vomiting, diarrhea, injection site reactions, chills, fever, sweating, hypersensitivity (anaphylaxis, hypotension, shortness of breath, pruritus, flushing, diffuse rash). ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Curium US LLC at 1-866-789-2211 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
👥 Use in Specific Populations ▾
8 USE IN SPECIFIC POPULATIONS Lactation: Temporarily discontinue breastfeeding. A lactating woman should pump and discard breast milk for at least 96 hours after Thallous Chloride Tl 201 Injection administration. ( 8.2 )
8.1Pregnancy Risk Summary There are no data on Thallous Chloride Tl 201 Injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Studies using human placentas demonstrate that thallous chloride Tl 201 crosses the placenta. No animal reproductive studies have been conducted.
All radiopharmaceuticals, including Thallous Chloride Tl 201 Injection have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering administration of Thallous Chloride Tl 201 Injection to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Thallous Chloride Tl 201 Injection and gestational timing of exposure. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 3% and 10% to 20%, respectively.
8.2Lactation Risk Summary Thallous chloride Tl 201 has been detected in the milk of lactating women. There are no data on the effects of thallous chloride Tl 201 on milk production or the effects of thallous chloride Tl 201 on the breastfed infant. Exposure of the breastfed infant to thallous chloride Tl 201 can be minimized by advising a lactating woman to temporarily discontinue breastfeeding and pump and discard milk for a minimum of 96 hours after administration of Thallous Chloride Tl 201 Injection.
Minimize close contact with infants if the administered dose would result in an effective dose greater than 1 mSv to the infant. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Thallous Chloride Tl 201 Injection and any potential adverse effects on the breastfed infant from Thallous Chloride Tl 201 Injection or from the underlying maternal condition.
8.4Pediatric Use The safety and effectiveness of Thallous Chloride Tl 201 Injection in pediatric patients have not been established.
8.5Geriatric Use Clinical studies of Thallous Chloride Tl 201 Injection for myocardial perfusion imaging did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently from younger subjects. Other reported experience has not revealed clinically relevant differences in the response of elderly in comparison to younger patients. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
🤰 Pregnancy ▾
8.1Pregnancy Risk Summary There are no data on Thallous Chloride Tl 201 Injection use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Studies using human placentas demonstrate that thallous chloride Tl 201 crosses the placenta. No animal reproductive studies have been conducted.
All radiopharmaceuticals, including Thallous Chloride Tl 201 Injection have the potential to cause fetal harm depending on the fetal stage of development and the magnitude of the radiation dose. If considering administration of Thallous Chloride Tl 201 Injection to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from Thallous Chloride Tl 201 Injection and gestational timing of exposure. The background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 3% and 10% to 20%, respectively.
🧒 Pediatric Use ▾
8.4Pediatric Use The safety and effectiveness of Thallous Chloride Tl 201 Injection in pediatric patients have not been established.
🧓 Geriatric Use ▾
8.5Geriatric Use Clinical studies of Thallous Chloride Tl 201 Injection for myocardial perfusion imaging did not include sufficient numbers of subjects aged younger than 65 years to determine whether they respond differently from younger subjects. Other reported experience has not revealed clinically relevant differences in the response of elderly in comparison to younger patients. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
🆘 Overdosage ▾
10 OVERDOSAGE In the event of the administration of an overdose of Thallous Chloride Tl 201 Injection, the absorbed dose to the patient should be reduced where possible by increasing the excretion of the radionuclide by forced diuresis with frequent voiding and stimulation of peristalsis.
🧬 Clinical Pharmacology ▾
12 CLINICAL PHARMACOLOGY
12.1Mechanism of Action Thallous chloride Tl 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous Chloride Tl 201 images have been found to visualize areas of infarction as “cold” or nonlabeled regions that were confirmed by electrocardiographic and enzyme changes.
Regions of transient myocardial ischemia corresponding to areas perfused by coronary arteries with partial stenoses have been visualized when Thallous Chloride Tl 201 Injection was administered in conjunction with an exercise stress test. Anatomic configurations may interfere with visualization of the right coronary artery territory.
12.2Pharmacodynamics The pharmacodynamics of thallous chloride Tl 201 have not been established.
12.3Pharmacokinetics Distribution After intravenous administration, thallous chloride Tl 201 clears from the blood with maximal concentration in normal myocardium occurring at about 10 minutes. It will, in addition, localize in parathyroid adenomas; it is not specific since it will localize to a lesser extent in sites of parathyroid hyperplasia and other abnormal tissues such as thyroid adenoma, neoplasia (e.g., parathyroid carcinoma), and sarcoid. Biodistribution is generally proportional to organ blood flow at the time of injection.
Blood clearance of thallous chloride Tl 201 is primarily by the myocardium, thyroid, liver, kidneys, and stomach with the remainder distributing fairly uniformly throughout the body. The dosimetry data in Table 1 reflect this distribution pattern and are based on a biological half-life of 2.4 days. Elimination Five minutes after intravenous administration only 5% to 8% of injected activity remained in the blood.
A biexponential disappearance curve was obtained, with 91.5 % of the blood radioactivity disappearing with a half-time of about 5 minutes. The remainder had a half-time of about 40 hours. Excretion Approximately 4% to 8% of the injected dose was excreted in the urine in the first 24 hours.
The whole body disappearance half-time was 9.8 ± 2.5 days. Kidney concentration was found to be about 3% of the injected activity and the testicular content was 0.15%. Net thyroid activity was determined to be only 0.2% of the injected dose, and the activity disappeared in 24 hours.
From anterior and posterior whole-body scans, it was determined that about 45% of the injected dose was in the large intestines and contiguous structures (liver, kidneys, abdominal musculature).
🧬 Mechanism of Action ▾
12.1Mechanism of Action Thallous chloride Tl 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous Chloride Tl 201 images have been found to visualize areas of infarction as “cold” or nonlabeled regions that were confirmed by electrocardiographic and enzyme changes.
Regions of transient myocardial ischemia corresponding to areas perfused by coronary arteries with partial stenoses have been visualized when Thallous Chloride Tl 201 Injection was administered in conjunction with an exercise stress test. Anatomic configurations may interfere with visualization of the right coronary artery territory.
📦 How Supplied / Storage and Handling ▾
16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied Thallous Chloride Tl 201 Injection is supplied as a clear, colorless solution in the following strength at calibration time: 207.2 MBq (5.6 mCi) per 5.6 mL (37 MBq (1 mCi) per mL) in a multiple-dose vial (NDC 69945-120-56) Storage and Handling Store Thallous Chloride Tl 201 Injection in the original container with radiation shielding at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Dispose of any unused product in accordance with all federal, state, and local laws and institutional requirements.
This preparation is for use by persons under license by the Nuclear Regulatory Commission or the relevant regulatory authority of an Agreement State.
📋 Description ▾
11 DESCRIPTION
11.1Drug Characteristics Thallous Chloride Tl 201 Injection is a sterile, radioactive diagnostic drug for intravenous use. Each mL contains 37 MBq (1 mCi) thallous chloride Tl 201 at calibration time and the following inactive ingredients: 9 mg sodium chloride and 0.9% (v/v) benzyl alcohol. The pH is adjusted to between 4.5 to 7.0 with hydrochloric acid and/or sodium hydroxide.
Thallium-201 is cyclotron produced. At the time of calibration it contains no more than 1% thallium-200, no more than 1% thallium-202, no more than 0.25% lead-203, and no less than 98% thallium-201 as a percentage of total activity. No carrier has been added.
The concentration of each radionuclidic contaminant changes with time. Figure 1 shows maximum concentration of thallium-200 (Tl 200) and thallium-202 (Tl 202) radionuclidic contaminants as a function of time. Figure 1.
Radionuclidic Contaminants figure 1
11.2Nuclear Physical Characteristics Thallium-201, with a physical half-life of 72.9 hours, decays by electron capture to mercury-201. Photons that are useful for detection and imaging are listed in Table 2. The lower energy x-rays obtained from the mercury-201 daughter of thallium-201 are recommended for myocardial imaging, because the mean percent disintegration at 68.9 to 80.3 keV is much greater than the combination of gamma-4 and gamma-6 mean percent disintegration.
Table 2. Principal Radiation Emission Data Radiation Mean Percent/ Disintegration Energy (keV) Gamma-4 2.7 135.3 Gamma-6 10.0 167.4 Mercury x-rays 94.4 68.9-80.3 The specific gamma ray constant for thallium-201 is
0.45R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) is 0.026 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide that results from interposition of various thicknesses of Pb is shown in Table 3.
For example, the use of 0.194 cm of lead will decrease the external radiation exposure by a factor of about 1,000. Table 3. Radiation Attenuation by Lead Shielding cm of Lead (Pb) Coefficient of Attenuation 0.026 0.5 0.052 10 -1 0.089 10 -2 0.194 10 -3 0.310 10 -4 To correct for physical decay of the radionuclide, the fractions that remain at selected intervals after calibration time are shown in Table 4.
Table 4. Physical Decay Chart for Thallium-201; Half-Life
72.9Hours Hours Fraction Remaining Hours Fraction Remaining 0* 1 66 0.53 6 0.95 72 0.50 12 0.89 78 0.48 18 0.84 84 0.45 24 0.80 90 0.43 30 0.75 96 0.40 36 0.74 108 0.36 42 0.67 120 0.32 48 0.63 132 0.29 54 0.60 144 0.25 60 0.57 * Calibration Time
💬 Information for Patients ▾
17 PATIENT COUNSELING INFORMATION Radiation Risk Advise patients of the radiation risk of Thallous Chloride Tl 201 Injection. Instruct patients to drink water to ensure adequate hydration prior to administration of Thallous Chloride Tl 201 Injection and to continue drinking and voiding frequently following administration to reduce radiation exposure [see Warnings and Precautions ( 5.3 )] . Pregnancy Inform pregnant women of the risk of fetal exposure to radiation dose if they undergo an imaging procedure with Thallous Chloride Tl 201 Injection [see Use in Specific Populations ( 8.1 )] .
Lactation Advise a lactating woman to temporarily discontinue breastfeeding and to pump and discard breastmilk for at least 96 hours after administration of Thallous Chloride Tl 201 Injection to minimize radiation exposure to a breastfed infant [see Use in Specific Populations ( 8.2 )] . Manufactured by: Curium US LLC Maryland Heights, MO 63043 Made in USA ©2025 Curium US LLC. Curium TM and the Curium logo are trademarks of a Curium company.
A120I0 CURIUM™
🧬 Pharmacokinetics ▾
12.3Pharmacokinetics Distribution After intravenous administration, thallous chloride Tl 201 clears from the blood with maximal concentration in normal myocardium occurring at about 10 minutes. It will, in addition, localize in parathyroid adenomas; it is not specific since it will localize to a lesser extent in sites of parathyroid hyperplasia and other abnormal tissues such as thyroid adenoma, neoplasia (e.g., parathyroid carcinoma), and sarcoid. Biodistribution is generally proportional to organ blood flow at the time of injection.
Blood clearance of thallous chloride Tl 201 is primarily by the myocardium, thyroid, liver, kidneys, and stomach with the remainder distributing fairly uniformly throughout the body. The dosimetry data in Table 1 reflect this distribution pattern and are based on a biological half-life of 2.4 days. Elimination Five minutes after intravenous administration only 5% to 8% of injected activity remained in the blood.
A biexponential disappearance curve was obtained, with 91.5 % of the blood radioactivity disappearing with a half-time of about 5 minutes. The remainder had a half-time of about 40 hours. Excretion Approximately 4% to 8% of the injected dose was excreted in the urine in the first 24 hours.
The whole body disappearance half-time was 9.8 ± 2.5 days. Kidney concentration was found to be about 3% of the injected activity and the testicular content was 0.15%. Net thyroid activity was determined to be only 0.2% of the injected dose, and the activity disappeared in 24 hours.
From anterior and posterior whole-body scans, it was determined that about 45% of the injected dose was in the large intestines and contiguous structures (liver, kidneys, abdominal musculature).
🧬 Pharmacodynamics ▾
12.2Pharmacodynamics The pharmacodynamics of thallous chloride Tl 201 have not been established.
🧪 Nonclinical Toxicology ▾
13 NONCLINICAL TOXICOLOGY
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
13.1Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate carcinogenic potential, mutagenic potential, or whether this drug affects fertility in males or females.
📄 Package Label / Principal Display Panel ▾
PRINCIPAL DISPLAY PANEL Thallous Chlloride TI 201 Injection DIAGNOSTIC Sterile, Non-Pyrogenic Solution For Intravenous Administration Multiple-dose vial Store at Controlled Room Temperature 20 ºto 25ºC (68 ºto 77ºF) [see USP]. Each milliliter contains 37 MBq (1 mCi) Thallous Chloride TI 201 (no carrier added) at date and time of calibration, 9 mg sodium chloride, and 0.9% (v/v) benzyl alcohol as a preservative. Sodium hydroxide and/or hydrochloric acid are added for pH adjustment.
The pH is between 4.5 and 7.0. Rx only CAUTION RADIOACTIVE MATERIAL Manufactured by: Curium US LLC Maryland Heights, MO 63043 Made in USA CURIUM™ A120V0 R11/2025 Display Panel A120C0
Reported adverse events (FAERS)
Top reported reactions
Age at onset
Reporter sex
Serious outcomes
Where does this data come from?
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope. |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |